SCHEMBL26280663

SCHEMBL26280663

CCCCO[C@H]1CCN(CC)C1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPC P11150 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
HRH3 Q9Y5N1 2/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36
GNAI3 P08754 2/20 0.33
GNAO1 P09471 2/20 0.33
GNAI1 P63096 2/20 0.33
NPC1 O15118 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
ESR1 P03372 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17033973 1.00 LIPC (0.38) LIPCLIPGHRH3CHRM2CHRM4
SCHEMBL26280657 1.00 LIPC (0.38) LIPCLIPGHRH3CHRM2CHRM4
SCHEMBL22856570 0.93 CHRM2 (0.41) LIPCLIPGCHRM2CHRM4CHRM5
SCHEMBL22793895 0.89 HRH3 (0.42) LIPCLIPGHRH3RAB9AMEN1
SCHEMBL25654271 0.87 HRH3 (0.40) LIPCLIPGHRH3GNAI3GNAO1
SCHEMBL25654272 0.87 HRH3 (0.40) LIPCLIPGHRH3GNAI3GNAO1
SCHEMBL16181654 0.85 LPAR1 (0.38) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL25468119 0.84 GBA1 (0.33) HRH3CYP2D6NPC1
SCHEMBL22906371 0.84 GBA1 (0.33) HRH3CYP2D6NPC1
SCHEMBL23518605 0.84 GBA1 (0.33) HRH3CYP2D6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295180-A1 PROTEIN DEGRADERS AND USES THEREOF MDM2, CUL1, PSMG3 LIPC 2747/4885LIPG 3398/4885HRH3 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.